{"document_type": "article", "byline": {"person": [{"role": "reported", "firstname": "Neil", "organization": "", "rank": 1, "lastname": "UNMACK"}], "original": "By NEIL UNMACK"}, "news_desk": "Business", "slideshow_credits": null, "abstract": null, "multimedia": [], "headline": {"kicker": "Breakingviews", "content_kicker": "Breakingviews", "main": "Johnson & Johnson Has Its Eye on Actelion"}, "print_page": null, "keywords": [{"value": "Actelion Pharmaceuticals Ltd", "is_major": "N", "rank": "1", "name": "organizations"}, {"value": "Johnson & Johnson", "is_major": "N", "rank": "2", "name": "organizations"}, {"value": "Drugs (Pharmaceuticals)", "is_major": "N", "rank": "3", "name": "subject"}, {"value": "Mergers, Acquisitions and Divestitures", "is_major": "N", "rank": "4", "name": "subject"}], "snippet": "But the market capitalization of Actelion, a Swiss drug maker, is high, so Johnson & Johnson would have to cut costs to make a deal work....", "source": "The New York Times", "lead_paragraph": "But the market capitalization of Actelion, a Swiss drug maker, is high, so Johnson & Johnson would have to cut costs to make a deal work.", "word_count": "425", "pub_date": "2016-11-25T21:22:24+0000", "subsection_name": "DealBook", "blog": [], "type_of_material": "News", "section_name": "Business Day", "web_url": "http://www.nytimes.com/2016/11/25/business/dealbook/johnson-johnson-actelion.html", "_id": "5838acd37c459f2525d0e5fb"}